Evidence map›Paper›PMID 34214118›Full record

ArticlePloS one2021

Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease.

Nancy A Niemuth, Dawn Fallacara, Cheryl A Triplett, Sanjay M Tamrakar, Alisha Rajbhandari, Clint Florence, Lucy Ward, Anthony Griffiths, Ricardo Carrion, Yenny Goez-Gazi and 15 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 1 country.

Nancy A NiemuthBattelle, Columbus, OH, United States of America.ORCID 0000-0001-5166-7743
Dawn FallacaraBattelle, Columbus, OH, United States of America.
Cheryl A TriplettBattelle, Columbus, OH, United States of America.
Sanjay M TamrakarBattelle, Columbus, OH, United States of America.
Alisha RajbhandariBattelle, Columbus, OH, United States of America.
Clint FlorenceNon-Clinical Advisor for Joint Program Manager Chemical, Biological, Radiological and Nuclear Medical (JPM CBRN Medical) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO CBRND), Fort Detrick, MD, United States of America.
Lucy WardAdvanced Vaccines & Immunologics, JPM CBRN Medical, JPEO CBRND, Fort Detrick, MD, United States of America.
Anthony GriffithsDepartment of Microbiology, National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, United States of America.
Ricardo CarrionTexas Biomedical Research Institute, San Antonio, TX, United States of America.
Yenny Goez-GaziTexas Biomedical Research Institute, San Antonio, TX, United States of America.
Kendra J AlfsonTexas Biomedical Research Institute, San Antonio, TX, United States of America.ORCID 0000-0001-6031-5360
Hilary M StaplesTexas Biomedical Research Institute, San Antonio, TX, United States of America.
Trevor BraselDepartment of Microbiology and Immunology/Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch (UTMB), Galveston, TX, United States of America.
Jason E ComerDepartment of Microbiology and Immunology/Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch (UTMB), Galveston, TX, United States of America.
Shane MasseyInstitutional Office of Regulated Nonclinical Studies, UTMB, Galveston, TX, United States of America.
Jeanon SmithInstitutional Office of Regulated Nonclinical Studies, UTMB, Galveston, TX, United States of America.
Andrew KocsisAnimal Resources Center, UTMB. Galveston, TX, United States of America.
Jake LowryAnimal Resources Center, UTMB. Galveston, TX, United States of America.
Sara C JohnstonVirology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, United States of America.
Aysegul NalcaCore Support Directorate, USAMRIID, Fort Detrick, MD, United States of America.ORCID 0000-0001-8581-7535
Arthur J GoffCommander's Special Staff, Deputy Director Research Program Office, USAMRIID, Fort Detrick, MD, United States of America.
Amy C ShurtleffMolecular Biology Division, USAMRIID, Fort Detrick, MD, United States of America.
Margaret L PittUSAMRIID, Fort Detrick, MD, United States of America.ORCID 0000-0003-0080-3260
John TrefryVaccines/Therapeutics Division (CBM), Defense Threat Reduction Agency, Fort Belvoir, Virginia, United States of America.
Michael P FayNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
Battelle · USUnited States Army Medical Research Institute of Infectious Diseases · USTexas Biomedical Research Institute · USThe University of Texas Medical Branch at Galveston · USBoston University · USDefense Threat Reduction Agency · USNational Institutes of Health · US

Funding

Regulatory Compliance CoreUC7AI095321 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Ronald O'Brien · 2014 to 2026
$159.3M
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
NIAID NIH HHS HHSN272201200003INIAID NIH HHS UC7 AI095321NIH HHS P51 OD011133
6 · The paper itself

Abstract

Filoviruses (Family Filoviridae genera Ebolavirus and Marburgvirus) are negative-stranded RNA viruses that cause severe health effects in humans and non-human primates, including death. Except in outbreak settings, vaccines and other medical countermeasures against Ebola virus (EBOV) will require testing under the FDA Animal Rule. Multiple vaccine candidates have been evaluated using cynomolgus monkeys (CM) exposed to EBOV Kikwit strain. To the best of our knowledge, however, animal model development data supporting the use of CM in vaccine research have not been submitted to the FDA. This study describes a large CM database (122 CM, 62 female and 60 male, age 2 to 9 years) and demonstrates the consistency of the CM model through time to death models and descriptive statistics. CMs were exposed to EBOV doses of 0.1 to 100,000 PFU in 33 studies conducted at three Animal Biosafety Level 4 facilities, by three exposure routes. Time to death was modeled using Cox proportional hazards models with a frailty term that incorporated study-to-study variability. Despite significant differences attributed to exposure variables, all CMs exposed to the 100 to 1,000 pfu doses commonly used in vaccine studies died or met euthanasia criteria within 21 days of exposure, median 7 days, 93% between 5 and 12 days of exposure. Moderate clinical signs were observed 4 to 5 days after exposure and preceded death or euthanasia by approximately one day. Viremia was detected within a few days of infection. Hematology indices were indicative of viremia and the propensity for hemorrhage with progression of Ebola viremia. Changes associated with coagulation parameters and platelets were consistent with coagulation disruption. Changes in leukocyte profiles were indicative of an acute inflammatory response. Increased liver enzymes were observed shortly after exposure. Taken together, these factors suggest that the cynomolgus monkey is a reliable animal model for human disease.

Indexed as

Disease Models, AnimalEbolavirusHemorrhagic Fever, EbolaMacaca fascicularisAnimalsFemaleHumansMale

Identifiers

PMID34214118
PMCPMC8253449
OpenAlexW3173777484

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.